ES2068592T3 - Forma galenica inyectable retardada. - Google Patents

Forma galenica inyectable retardada.

Info

Publication number
ES2068592T3
ES2068592T3 ES91910873T ES91910873T ES2068592T3 ES 2068592 T3 ES2068592 T3 ES 2068592T3 ES 91910873 T ES91910873 T ES 91910873T ES 91910873 T ES91910873 T ES 91910873T ES 2068592 T3 ES2068592 T3 ES 2068592T3
Authority
ES
Spain
Prior art keywords
essuras
estras
administration
galenic form
inactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910873T
Other languages
English (en)
Inventor
Uribe Juan Angeles
Garza Flores Josue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aplicaciones Farmaceuticas SA de CV
Original Assignee
Aplicaciones Farmaceuticas SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aplicaciones Farmaceuticas SA de CV filed Critical Aplicaciones Farmaceuticas SA de CV
Application granted granted Critical
Publication of ES2068592T3 publication Critical patent/ES2068592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

FORMULACION DE LIBERACION PROLONGADA DESTINADA A LA ADMINISTRACION POR INYECCION PARENTERAL, CONSTITUIDA DE MICROBOLITAS CALIBRADAS SOLIDAS (5-300 (MU)M) QUE COMPRENDE UNA SUSTANCIA FARMACEUTICAMENTE ACTIVA (POR EJEMPLO: MORFINA) CONTENIDA EN ESTRUCTURAS ESFERICAS FORMADAS POR UNA O VARIAS SUSTANCIAS DE SOPORTE FARMACOLOGICAMENTE INACTIVAS (POR EJEMPLO: COLESTEROL) PRESENTES NATURALMENTE EN EL ORGANISMO RECEPTOR, FARMACODINAMICAMENTE INACTIVAS EN LAS DOSIS DE ADMINISTRACION DE DICHA FORMA GALENICA, QUE TIENEN UN PUNTO DE FUSION SUPERIOR A 60 C Y ESTABLES EN ESTADO SOLIDO EN EL MEDIO FISIOLOGICAMENTE RECEPTOR. LA FORMA GALENICA PERMITE RALENTIZAR Y PROLONGAR EL EFECTO DE SUSTANCIAS ACTIVAS QUE SE DISUELVEN MUY RAPIDAMENTE EN MEDIOS FISIOLOGICOS (ACTUANDO SOBRE EL SISTEMA NERVIOSO CENTRAL O NEUROVEGETATIVO, COMO VASODILATADORES, ANTIHISTAMINICOS, HORMONAS, ANTICONCEPTIVOS...).
ES91910873T 1990-06-14 1991-06-12 Forma galenica inyectable retardada. Expired - Lifetime ES2068592T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9007417A FR2663224B1 (fr) 1990-06-14 1990-06-14 Forme galenique parenterale.

Publications (1)

Publication Number Publication Date
ES2068592T3 true ES2068592T3 (es) 1995-04-16

Family

ID=9397599

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910873T Expired - Lifetime ES2068592T3 (es) 1990-06-14 1991-06-12 Forma galenica inyectable retardada.

Country Status (33)

Country Link
US (1) US5643604A (es)
EP (1) EP0487674B1 (es)
JP (1) JP2690398B2 (es)
KR (1) KR0157438B1 (es)
CN (1) CN1058608C (es)
AT (1) ATE117546T1 (es)
AU (1) AU643540B2 (es)
BG (1) BG61178B1 (es)
BR (1) BR9105782A (es)
CA (1) CA2064861C (es)
CZ (1) CZ286199B6 (es)
DE (1) DE69107026T2 (es)
DK (1) DK0487674T3 (es)
ES (1) ES2068592T3 (es)
FI (1) FI107697B (es)
FR (1) FR2663224B1 (es)
GR (1) GR3015809T3 (es)
HU (1) HU219461B (es)
IE (1) IE69172B1 (es)
IL (1) IL98458A (es)
NO (2) NO920576L (es)
NZ (1) NZ238543A (es)
PH (1) PH30243A (es)
PL (1) PL167177B1 (es)
PT (1) PT97976B (es)
RO (1) RO110198B1 (es)
RU (1) RU2095055C1 (es)
SK (1) SK279867B6 (es)
TN (1) TNSN91047A1 (es)
TW (1) TW205511B (es)
UY (1) UY23239A1 (es)
WO (1) WO1991019485A1 (es)
ZA (1) ZA914549B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9819272D0 (en) * 1998-09-03 1998-10-28 Andaris Ltd Microparticles
US6495535B1 (en) 1999-03-26 2002-12-17 Pozen Inc. High potency dihydroergotamine compositions
DE19940795A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan
ATE288687T1 (de) * 2001-09-27 2005-02-15 Cognis Deutschland Gmbh Kugelförmige sterinzubereitungen, deren herstellung und verwendung
EP1448228A4 (en) * 2001-10-24 2007-01-24 Marco Pappagallo TREATMENT OF POSTOPERATIVE PAIN
WO2003053292A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
RU2205634C1 (ru) * 2002-06-18 2003-06-10 Нестерук Владимир Викторович Лекарственное средство, обладающее противорвотным действием
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
EP1663161B1 (en) * 2003-06-13 2015-01-14 Skendi Finance, Ltd. Slow release estradiol-progesterone formulation
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
PT1838716E (pt) 2005-01-05 2011-07-15 Lilly Co Eli Di-hidrato de pamoato de olanzapina
WO2007072491A2 (en) * 2005-12-21 2007-06-28 Baskaran Chandrasekar Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same
AU2007325780B9 (en) 2006-11-27 2013-09-12 H. Lundbeck A/S Heteroaryl amide derivatives
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20110104289A1 (en) * 2008-04-14 2011-05-05 Posi Visionary Solutions Llp Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
RU2395139C1 (ru) * 2009-04-10 2010-07-20 Российская Федерация, от имени которой выступает Государственная корпорация по атомной энергии "Росатом" Способ изготовления волновода переменного сечения
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
UY33103A (es) 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP2523666B8 (en) * 2010-01-14 2016-04-06 Asarina Pharma AB A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
RU2576236C1 (ru) * 2014-08-22 2016-02-27 Александр Александрович Кролевец Способ получения нанокапсул антибиотиков в агар-агаре
RU2577689C1 (ru) * 2014-08-26 2016-03-20 Александр Александрович Кролевец Способ получения нанокапсул антибиотиков в агар-агаре
RU2578408C1 (ru) * 2014-09-10 2016-03-27 Александр Александрович Кролевец Способ получения нанокапсул алкалоидов
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
DK123067B (da) * 1970-09-25 1972-05-15 Niro Atomizer As Fremgangsmåde til behandling af et pulverformigt, fedtholdigt mælkeprodukt.
JPS5017525A (es) * 1973-06-14 1975-02-24
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4244949A (en) * 1978-04-06 1981-01-13 The Population Council, Inc. Manufacture of long term contraceptive implant
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
JPS61174940A (ja) * 1985-01-29 1986-08-06 Oogawara Kakoki Kk ワックス類コーテイング単核状マイクロカプセルおよびその製造方法
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
IL79407A (en) * 1985-08-01 1991-03-10 Theragenics Corp System and method for delivering insoluble material into a living body
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
DE3777721D1 (de) * 1986-08-11 1992-04-30 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
ATE109941T1 (de) * 1987-04-06 1994-09-15 Endocon Inc Durch schnellschmelzen hergestellte medizinische implantate.
US4892734A (en) * 1987-04-06 1990-01-09 Endocon, Inc. Dispensing paste for forming medicinal pellets
US4748024A (en) 1987-04-06 1988-05-31 Endocon, Inc. Flash flow fused medicinal implants
EP0366058A3 (en) * 1988-10-27 1991-03-20 Abbott Laboratories Controlled-release delivery device, method for producing device, and method of using device
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.

Also Published As

Publication number Publication date
KR0157438B1 (ko) 1998-11-16
CA2064861C (fr) 2000-08-01
IL98458A0 (en) 1992-07-15
GR3015809T3 (en) 1995-07-31
AU643540B2 (en) 1993-11-18
BR9105782A (pt) 1992-08-18
FI920661A0 (fi) 1992-02-14
PT97976A (pt) 1992-04-30
UY23239A1 (es) 1991-07-12
DE69107026D1 (de) 1995-03-09
EP0487674A1 (fr) 1992-06-03
KR920702212A (ko) 1992-09-03
TW205511B (es) 1993-05-11
CA2064861A1 (fr) 1991-12-15
PH30243A (en) 1997-02-05
IE912018A1 (en) 1991-12-18
CN1057960A (zh) 1992-01-22
DE69107026T2 (de) 1995-08-31
NZ238543A (en) 1993-08-26
TNSN91047A1 (fr) 1992-10-25
BG95911A (bg) 1993-12-24
PL167177B1 (pl) 1995-08-31
DK0487674T3 (da) 1995-06-26
ZA914549B (en) 1992-03-25
NO302927B1 (no) 1998-05-11
PT97976B (pt) 1998-11-30
AU8066791A (en) 1992-01-07
CN1058608C (zh) 2000-11-22
JPH05501268A (ja) 1993-03-11
NO920576L (no) 1992-04-08
CS181591A3 (en) 1992-06-17
WO1991019485A1 (fr) 1991-12-26
EP0487674B1 (fr) 1995-01-25
IL98458A (en) 1995-12-31
IE69172B1 (en) 1996-08-07
FR2663224B1 (fr) 1995-01-20
FI107697B (fi) 2001-09-28
RU2095055C1 (ru) 1997-11-10
US5643604A (en) 1997-07-01
BG61178B1 (bg) 1997-02-28
HU219461B (hu) 2001-04-28
PL290678A1 (en) 1992-06-26
ATE117546T1 (de) 1995-02-15
SK279867B6 (sk) 1999-04-13
HUT61458A (en) 1993-01-28
NO920576D0 (no) 1992-02-13
JP2690398B2 (ja) 1997-12-10
CZ286199B6 (cs) 2000-02-16
FR2663224A1 (fr) 1991-12-20
HU9200775D0 (en) 1992-05-28
RO110198B1 (ro) 1995-11-30

Similar Documents

Publication Publication Date Title
ES2068592T3 (es) Forma galenica inyectable retardada.
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
FI94094B (fi) Kantajakoostumus kestovaikutteiselle lääkeainevalmisteelle
DK0831827T3 (da) Nye formuleringer til transdermal levering af pergolid
PT1076644E (pt) Aminotetralinas substituidas emn como ligandos para o receptor de neuropeptideoy y5 util no tratamento da obesidade e de outras perturbacoes
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
WO2000013662A8 (en) Medicated chewing gum delivery system for nicotine
ES2061848T3 (es) Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
YU48766B (sh) Postupak za dobijanje farmaceutskog preparata za oralnu primenu sa usporenim oslobađanjem aktivne supstance bez rastvarača
ES2179832T3 (es) Formas de administracion orales con contenido en flupirtina solida, con liberacion controlada del principio activo.
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
ATE206042T1 (de) Verfahren zur herstellung von niedrigdosierten arzneimitteln
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
ATE212543T1 (de) Pharmazeutische zusammensetzung aus stabilisierten lipophilen matrizen mit kontrollierter wirkstofffreisetzung
DK1154776T3 (da) Farmaceutisk sammensætning, indeholdende desoxypeganin til behandling af alkoholisme
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
AR010942A1 (es) Derivado de la piperidinilmetiloxazolidinona, los procedimientos para prepararlo, su empleo en la elaboracion de medicamentos, las preparacionesfarmaceuticas que lo contienen y un procedimiento para elaborar estas preparaciones farmaceuticas.
DE69803772D1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 487674

Country of ref document: ES